Clinical Trials Browser

Active not recruiting × olaparib × Thoracic × Clear all

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03775486 2026-02-10

ORION

Phase 2 Active not recruiting

401 enrolled 26 charts

Thoracic

Non-small Cell Lung Cancer NSCLC

NCT02734004 2026-01-29

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT04728230 2025-12-18

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

Phase 1/2 Active not recruiting

63 enrolled

Thoracic

Lung Neoplasms

NCT03334617 2025-10-27

HUDSON

Phase 2 Active not recruiting

528 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02498613 2025-09-25

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Phase 2 Active not recruiting

122 enrolled 16 charts

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04380636 2025-08-17

MK-7339-012

Phase 3 Active not recruiting

870 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04624204 2025-07-02

MK 7339-013

Phase 3 Active not recruiting

672 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

Clinical Trials

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

ORION

MEDIOLA

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

HUDSON

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

MK-7339-012

MK 7339-013